AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01937637 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Intervention for Breathlessness
Description: Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
Study NCT02678689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)
Study NCT02678689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraventricular access device
Description: Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
Study NCT00098254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006 (Sorafenib)
Description: Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
Study NCT01863927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research intervention
Description: After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
Study NCT02892682 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BLOOD TEST
Study NCT05053048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SL-PLUS-Stem for total hip arthroplasty
Description: Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
Study NCT01083940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized reminders on hypertension intensification
Description: Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
Study NCT01913639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study NCT01913639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Study NCT01913639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT01913639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT04361032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection
Description: Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
Study NCT04361032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
Study NCT02385578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an educational intervention
Description: the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on
Study NCT01391351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples in patients receiving Taxol and carboplatin chemotherapy :~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy
Study NCT01391351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy
Study NCT04261179 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lymphoseek
Description: 50 μg microgram(s), timepoint: 30-60 minutes
Study NCT04261179 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nanocoll
Description: 500 μg microgram(s), timepoint: 30-60 minutes
Study NCT02872727 — intervention group
Intervention type: OTHER
Intervention: Respiratoy health, biological investigations
Description: Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
Study NCT00373932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached exercise persistence intervention
Description: Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
Study NCT00373932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitored exercise persistence intervention
Description: Self-monitoring of symptoms and exercise using a mobile device
Study NCT00924469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
Study NCT00924469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
Study NCT00924469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
Study NCT00924469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
Study NCT00924469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
Study NCT00924469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
Study NCT02433548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block
Description: injection of 30 mLs below the fascia iliaca
Study NCT02433548 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: subcutaneous of 5 cc of normal saline
Study NCT03648203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enabled Asthma Management System
Description: See description of arm
Study NCT04315415 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Silk Voice
Description: Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
Study NCT00630058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424(H), PEG-IFN-a-2b, RBV
Description: MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Study NCT05053048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SL-PLUS-Stem for total hip arthroplasty
Description: Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
Study NCT03891472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.
Description: mFOLFIRINOX > SBRT > mFOLFIRINOX > Surgical Intervention
Study NCT00630058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (L), PEG-IFN-a-2b, RBV
Description: MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Study NCT01448954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B oral
Description: Once daily for 28 days
Study NCT01448954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral
Description: Once daily for 28 days
Study NCT02771730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-mgag
Description: A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
Study NCT02771730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvC150
Description: A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
Study NCT02771730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral sucrose capsules
Study NCT02771730 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
Study NCT02771730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
Study NCT05232513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand massage
Description: Hand massage is an initiative that improves the communication between the massager and the individual, reduces anxiety, and provides comfort and relaxation.
Study NCT02977884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Complete Health Improvement Program
Description: CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
Study NCT01597505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: 250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
Study NCT01597505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
Study NCT01597505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
Study NCT00910520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
Study NCT00910520 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
Study NCT00910520 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal saline (placebo) injected into the detrusor at Day 1.
Study NCT03987256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial rehabilitation protocol
Description: During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
Study NCT03987256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial rehabilitation protocol
Description: During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
Study NCT03987256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needling with PRP
Description: In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure.
Study NCT03987256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needling with saline solution
Description: In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure.
Study NCT03467438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-l-carnosine
Description: Patients will be asked to take the investigational product as already mentioned (blindly).
Study NCT03467438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be asked to take placebo as already mentioned (blindly).
Study NCT03064854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion
Study NCT03064854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion
Study NCT03064854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion
Study NCT03064854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous infusion
Study NCT03064854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion
Study NCT03064854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion
Study NCT03064854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Subcutaneous injection
Study NCT00452673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
Study NCT00452673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
Study NCT01582178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm Water Immersion Colonoscopy
Description: Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
Study NCT01582178 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cool Water Immersion Colonoscopy
Description: Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
Study NCT03414996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
Study NCT03414996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
Study NCT03911661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fearon warfarin dosing algorithm
Description: Blood test drawn by patient using a point of care INR monitor
Study NCT03911661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Historical management of warfarin by patient's usual care providers
Study NCT02937142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior group therapy
Description: 1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
Study NCT02937142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Education on ADHD, and ADHD medication if indicated
Study NCT02937142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Education on ADHD, and ADHD medication if indicated
Study NCT00130793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation
Description: 1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
Study NCT00130793 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: zoster vaccine live (Oka/Merck) frozen formulation
Description: 1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
Study NCT04110366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: Vaccination with live attenuated influenza vaccine (LAIV)
Study NCT04110366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle control
Description: Vehicle control nasal challenge
Study NCT02406989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Study Drug
Study NCT02406989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MS-553
Study NCT00818064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Single s.c. injection (per dose cohort)
Study NCT00818064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single s.c. injection (per dose cohort)
Study NCT05016011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Description: Human umbilical cord-derived mesenchymal stem cells
Study NCT05016011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marrow cellution
Description: Patients will undergo marrow cellution surgical procedure.
Study NCT01002664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2
Description: 30 mg/day (two 15 mg capsules) Qd for 12 weeks